## APPENDIX 1: Changes to the wound care market share agreements as the result of consultation feedback

HSS Subcategory	Change	Reason for change
All six	<b>Listing date:</b> changed from 1 October 2016 to 1 November 2016.	Recommendation for Board decision delayed by one month to allow further engagement with DHBs.
All six	<b>Transition period:</b> Changed from six months to eight months.	DHBs may not be able to manage the required changes in six months.
	<b>HSS start date:</b> changed from 1 April 2017 to 1 July 2017	
	<b>DV compliance period:</b> First compliance period changed from 1 April 2017 – 30 June 2018, to 1 July 2017 – 30 June 2018.	
All six	<b>Stock holding:</b> Minimum stock holding in New Zealand increased from two months to three months of normal sales.	
IV pressure pads (sterile)	<b>HSS brand:</b> Chushavan brand excluded from HSS Subcategory scope and will not be listed. The Cesablic brand will be the only HSS brand.	The Chushavan product is not considered to be an IV pressure pad due to its lower pad profile.
	<b>HSS subcategory scope:</b> description changed to reflect required specifications.	
Foam non-adhesive dressings	<b>HSS brand:</b> PolyMem and PolyMax brands excluded from scope. PolyMem and PolyMax brands will continue to be listed and available under USL non- market share contract.	DHBs provided feedback that they do not use PolyMem and PolyMax foam dressings in the same way clinically as they do other foam dressings included in scope.
	<b>HSS subcategory scope:</b> description changed to reflect exclusion of surfactant containing foam dressings with low exudate management properties.	
Foam adhesive dressings (with and without border)	<b>HSS subcategory scope:</b> description changed to reflect exclusion of surfactant containing foam dressings with low exudate management properties	DHBs provided feedback that they do not use PolyMem and PolyMax foam dressings in the same way clinically as they do other foam dressings included in scope.
Combine dressings (sterile)	<b>HSS products:</b> Removal of duplicate products and addition of packaging information in product description (paper/PE or paper/paper).	For ease of reference and clarity when listed in the Pharmaceutical Schedule.